Across TCGA pan-cancer cohorts, RBMXL1 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated RBMXL1 data layer compared with 3 for mutation status and 6 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher RBMXL1 RNA is associated with better overall survival. In most high-consensus cancer types, elevated RBMXL1 expression acts as an unfavorable survival marker, although some lineages such as SCLC and BRCA show a favorable association.
SCLC, BRCA, and KIRC are the cancer types where RBMXL1 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.